PSNL241220P7500
- 0.00
- 0.000.00%
Personalis Newsroom
Personalis to Participate at Upcoming Investor Conferences
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Raises Target Price to $5
Personalis: Promising Growth in Biopharma Sales Amidst Strategic Challenges – Hold Rating Maintained
Cathie Wood's ARK Investment Bought 266.8K Shares of Personalis Today
Here's Why We're Not Too Worried About Personalis' (NASDAQ:PSNL) Cash Burn Situation
Personalis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
A Quick Look at Today's Ratings for Personalis(PSNL.US), With a Forecast Between $7 to $9
Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ...
Personalis Price Target Lowered to $7 From $8 at Lake Street
Have Insiders Sold Personalis Shares Recently?
12 Health Care Stocks Moving In Thursday's Pre-Market Session
What Analysts Are Saying About Personalis Stock
H.C. Wainwright Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $9
Needham Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7.25
Express News | Needham Reiterates Buy on Personalis, Maintains $7.25 Price Target
Personalis Analyst Ratings
Personalis: Strong Revenue Growth and Strategic Advances Justify Buy Rating
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating
TD Cowen Remains a Buy on Personalis (PSNL)